Literature DB >> 15851405

Akt activation in renal cell carcinoma: contribution of a decreased PTEN expression and the induction of apoptosis by an Akt inhibitor.

S Hara1, M Oya, R Mizuno, A Horiguchi, K Marumo, M Murai.   

Abstract

BACKGROUND: Akt has been implicated in the oncogenesis of human malignant tumors, because Akt regulates many key effector molecules involved in cell survival. PTEN (phosphatase and tensin homolog deleted on chromosome 10) negatively regulates Akt activation.
MATERIALS AND METHODS: The expression of phosphorylated Akt (p-Akt), total Akt and PTEN was analyzed by Western blotting in 45 renal cell carcinoma (RCC) patients. The Bad and phosphorylated Bad (p-Bad) statuses were analyzed in 20 RCC patients. A phosphatidylinositol ether analog was used as an Akt inhibitor to treat four RCC cell lines, namely Caki-1, KU19-20, SW839 and Caki-2.
RESULTS: The PTEN expression in RCC was observed to decrease and p-Akt expression to increase significantly in comparison with that in the corresponding normal kidney tissue. The PTEN expression inversely correlated with the p-Akt expression. These alterations were specific for clear cell type RCC, but not for papillary or chromophobe type RCC. Alterations in Bad phosphorylation were also specifically observed in clear cell type. The Akt inhibitor induced apoptosis in KU19-20 and Caki-2 cells with a high Akt activity.
CONCLUSIONS: A decreased expression of PTEN may be an underlying mechanism for Akt activation. An Akt inhibitor may be a therapeutic option for a subset of RCC with an elevated Akt activity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15851405     DOI: 10.1093/annonc/mdi182

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  23 in total

Review 1.  Systemic therapy for metastatic non-clear-cell renal cell carcinoma: recent progress and future directions.

Authors:  Simon Chowdhury; Marc R Matrana; Christopher Tsang; Bradley Atkinson; Toni K Choueiri; Nizar M Tannir
Journal:  Hematol Oncol Clin North Am       Date:  2011-08       Impact factor: 3.722

2.  Papillary renal cell carcinoma is associated with PTEN hamartoma tumor syndrome.

Authors:  Jessica L Mester; Ming Zhou; Nichole Prescott; Charis Eng
Journal:  Urology       Date:  2012-03-03       Impact factor: 2.649

Review 3.  Perspectives in drug development for metastatic renal cell cancer.

Authors:  Bristi Basu; Tim Eisen
Journal:  Target Oncol       Date:  2010-08-06       Impact factor: 4.493

Review 4.  Signaling pathways in renal cell carcinoma.

Authors:  Gowrishankar Banumathy; Paul Cairns
Journal:  Cancer Biol Ther       Date:  2010-10-01       Impact factor: 4.742

5.  Candidate tumor suppressor and pVHL partner Jade-1 binds and inhibits AKT in renal cell carcinoma.

Authors:  Liling Zeng; Ming Bai; Amit K Mittal; Wassim El-Jouni; Jing Zhou; David M Cohen; Mina I Zhou; Herbert T Cohen
Journal:  Cancer Res       Date:  2013-07-01       Impact factor: 12.701

Review 6.  Predictive biomarkers for the activity of mammalian target of rapamycin (mTOR) inhibitors.

Authors:  Catherine Delbaldo; Sébastien Albert; Chantal Dreyer; Marie-Paule Sablin; Maria Serova; Eric Raymond; Sandrine Faivre
Journal:  Target Oncol       Date:  2011-04-28       Impact factor: 4.493

7.  Aneuploidy, oncogene amplification and epithelial to mesenchymal transition define spontaneous transformation of murine epithelial cells.

Authors:  Hesed M Padilla-Nash; Nicole E McNeil; Ming Yi; Quang-Tri Nguyen; Yue Hu; Danny Wangsa; David L Mack; Amanda B Hummon; Chanelle Case; Eric Cardin; Robert Stephens; Michael J Difilippantonio; Thomas Ried
Journal:  Carcinogenesis       Date:  2013-04-25       Impact factor: 4.944

8.  Identifying mRNA targets of microRNA dysregulated in cancer: with application to clear cell Renal Cell Carcinoma.

Authors:  Huiqing Liu; Angela R Brannon; Anupama R Reddy; Gabriela Alexe; Michael W Seiler; Alexandra Arreola; Jay H Oza; Ming Yao; David Juan; Louis S Liou; Shridar Ganesan; Arnold J Levine; W K Rathmell; Gyan V Bhanot
Journal:  BMC Syst Biol       Date:  2010-04-27

Review 9.  Aerobic glycolysis: a novel target in kidney cancer.

Authors:  Brian Shuch; W Marston Linehan; Ramaprasad Srinivasan
Journal:  Expert Rev Anticancer Ther       Date:  2013-06       Impact factor: 4.512

Review 10.  Resistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): molecular basis, preclinical data, and counteracting strategies.

Authors:  Annemilaï Tijeras-Raballand; Cindy Neuzillet; Anne Couvelard; Maria Serova; Armand de Gramont; Pascal Hammel; Eric Raymond; Sandrine Faivre
Journal:  Target Oncol       Date:  2012-08-25       Impact factor: 4.493

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.